Investors report 1.83% PetMed Express (PETS) stake in new Schedule 13D filing

Rhea-AI Filing Summary

PetMed Express, Inc. received a Schedule 13D from Diveroli Investment Group LLC and Kingbird Ventures LLC disclosing a stake in its common stock. The reporting persons beneficially own 391,757 shares, representing 1.83% of PetMed’s outstanding common stock, based on 21,400,495 shares outstanding as of January 30, 2026.

The shares are held in the name of Kingbird Ventures LLC, with Diveroli Investment Group LLC acting as its authorized representative. The investors describe their principal business as investing in public and private companies and state they may buy more or sell shares over time depending on market and company factors, but do not currently have specific plans for corporate changes at PetMed.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

PetMed Express, Inc.

(Name of Issuer)

Common Stock, $0.001 par value per share

(Title of Class of Securities)

716382106

(CUSIP Number)

Aharon Diveroli
Diveroli Investment Group LLC, 848 Brickell Ave., Suite PH5
Miami, FL, 33131
305-202-0630

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

01/11/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 716382106

1

Name of reporting person

Diveroli Investment Group LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 391,757.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 391,757.00

11

Aggregate amount beneficially owned by each reporting person

391,757.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

1.83 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

Based on 21,400,495 shares of Common Stock outstanding as of January 30, 2026, as reported in the Issuer's Form 10-Q for the quarterly period ended December 31, 2025 filed with the Securities and Exchange Commission on February 5, 2026.

SCHEDULE 13D

CUSIP No. 716382106

1

Name of reporting person

Kingbird Ventures LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

WYOMING

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 391,757.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 391,757.00

11

Aggregate amount beneficially owned by each reporting person

391,757.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

1.83 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

Based on 21,400,495 shares of Common Stock outstanding as of January 30, 2026, as reported in the Issuer's Form 10-Q for the quarterly period ended December 31, 2025 filed with the Securities and Exchange Commission on February 5, 2026.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, $0.001 par value per share
(b)	Name of Issuer: PetMed Express, Inc.
(c)	Address of Issuer's Principal Executive Offices: 420 South Congress Avenue,, Delray Beach,, FLORIDA , 33445.
Item 2.	Identity and Background
(a)	Diveroli Investment Group LLC and Kingbird Ventures LLC (the "Reporting Persons"),
(b)	The Reporting Persons have a business address of 848 Brickell Ave., Suite PH5, Miami, FL, 33131
(c)	Reported shares are held in the name of Kingbird Ventures LLC, and Diveroli Investment Group LLC is its authorized representative. The principal business of the Reporting Persons is investing in public and private companies.
(d)	N/A
(e)	N/A
(f)	Diveroli Investment Group LLC is a Delaware limited liability company. Kingbird Ventures LLC is a Wyoming limited liability company.
Item 3.	Source and Amount of Funds or Other Consideration
	The Reporting Persons have utilized certain investment funds in their possession as the consideration for the acquisition of shares of common stock of the Issuer, as disclosed in this Schedule 13D.
Item 4.	Purpose of Transaction
	As the holders of a significant interest in the Issuer, the Reporting Persons may have influence over the corporate activities of the Issuer, including activities which may relate to the transactions described in clauses (a) through (j) of the instructions to Item 4 of Schedule 13D. The Reporting Persons from time to time intends to review their investments in the Issuer on the basis of various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the shares of common stock of the Issuer (the "Shares") in particular, as well as other developments and other investment opportunities. Based upon such review, the Reporting Persons will take such actions in the future as the Reporting Persons may deem appropriate in light of the circumstances existing from time to time. If the Reporting Persons believe that further investment in the Issuer is attractive, whether because of the market price of the Shares or otherwise, they may acquire Shares or other securities of the Issuer either in the open market or in privately negotiated transactions. Similarly, depending on market and other factors, the Reporting Persons may determine to dispose of some or all of the Shares currently owned by the Reporting Persons or otherwise acquired by the Reporting Persons either in the open market or in privately negotiated transactions. The Reporting Persons may also issue press releases and/or reports expressing their views and concerns regarding the Issuer's performance, valuations of the Issuer, investor interest in the Issuer, and potential strategic transactions involving the Issuer. Except as set forth in this Schedule 13D, the Reporting Persons have not formulated any plans or proposals which relate to or would result in: (a) the acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) a sale or transfer of a material amount of the assets of the Issuer or any of its subsidiaries; (d) any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (e) any material change in the present capitalization or dividend policy of the Issuer; (f) any other material change in the Issuer's business or corporate structure; (g) any change in the Issuer's charter or bylaws or other instrument corresponding thereto or other action which may impede the acquisition of control of the Issuer by any person; (h) causing a class of the Issuer's securities to be deregistered or delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (i) a class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Act; or (j) any action similar to any of those enumerated above.
Item 5.	Interest in Securities of the Issuer
(a)	391,757.00 shares of Common Stock, $0.001 par value per share, which constitutes a beneficial ownership percentage of 1.83% as of the date of this Schedule 13D. Based on 21,400,495 shares of Common Stock outstanding as of January 30, 2026, as reported in the Issuer's Form 10-Q for the quarterly period ended December 31, 2025 filed with the Securities and Exchange Commission on February 5, 2026.
(b)	391,757.00 shares of Common Stock, $0.001 par value per share.
(c)	N/A
(d)	N/A
(e)	N/A
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	N/A
Item 7.	Material to be Filed as Exhibits.
	EXHIBIT 99.1 JOINT FILING AGREEMENT

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Diveroli Investment Group LLC

Signature:	/s/ Aharon Diveroli
Name/Title:	Aharon Diveroli/Chief Investment Officer
Date:	02/11/2026

Kingbird Ventures LLC

Signature:	/s/ Aharon Diveroli
Name/Title:	Aharon Diveroli/Chief Investment Officer
Date:	02/11/2026

FAQ

What stake in PetMed Express (PETS) is reported in this Schedule 13D?

The filing reports beneficial ownership of 391,757 PetMed Express shares, equal to 1.83% of the company’s common stock. This percentage is calculated using 21,400,495 shares outstanding as of January 30, 2026, as disclosed in PetMed’s Form 10-Q.

Who are the reporting persons in the PetMed Express (PETS) Schedule 13D?

The reporting persons are Diveroli Investment Group LLC and Kingbird Ventures LLC. The shares are held in the name of Kingbird Ventures LLC, while Diveroli Investment Group LLC is identified as its authorized representative. Both entities describe their primary business as investing in public and private companies.

How many PetMed Express (PETS) shares do the reporting persons beneficially own?

The reporting persons beneficially own 391,757 shares of PetMed Express common stock. They report shared voting and shared dispositive power over all 391,757 shares, with no sole voting or sole dispositive power indicated in the filing’s ownership tables.

What influence might the reporting persons have on PetMed Express (PETS)?

The filing notes the investors, as significant holders, may have influence over PetMed’s corporate activities. They state they may review their investment and could buy more or sell shares, but currently have no specific plans for mergers, board changes, or other major corporate actions.

How was the 1.83% ownership in PetMed Express (PETS) calculated?

The 1.83% figure is based on 21,400,495 PetMed common shares outstanding as of January 30, 2026. That outstanding share count comes from PetMed’s Form 10-Q for the quarter ended December 31, 2025, filed with the SEC on February 5, 2026.

What is the purpose of the PetMed Express (PETS) Schedule 13D filing?

The Schedule 13D discloses the investors’ ownership and intentions regarding PetMed Express stock. The reporting persons describe using their investment funds to acquire shares and state they may buy more or sell shares depending on company performance, market conditions, and other opportunities.